Inovio Pharmaceuticals (INO) Spikes on AstraZeneca Deal

Inovio Pharmaceuticals Inc

shares rose 23.9% to $8.04 following the announcement of a licensing deal with AstraZeneca plc unit. Inovio Pharma reported a Q2 loss of $0.09 per share on revenue of $5.3 million. Share volume was 16.3 million, overwhelming an all-day average of just over one million.